Surgery Websites
Transplant Surgery »  Meet the Team »  Hepatology »  Neil Mehta, M.D.
Neil Mehta, M.D.

Neil Mehta, M.D.

Assistant Professor of Medicine
General Hepatology and Liver Transplantation
Department of Medicine

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357     
San Francisco, CA 94143-0358
(415) 476-6422 - Phone
(415) 476-0659 - Fax
Open Popup
  • Johns Hopkins University, BA, Neuroscience, 1998-2002
  • University of California, San Francisco School of Medicine, MD, 2002-2006
  • Hospital of the University of Pennsylvania, Intern, Internal Medicine, 2006-2007
  • Hospital of the University of Pennsylvania, Resident, Internal Medicine, 2007-2009
  • University of California, San Francisco, Fellow, Gastroenterology, 2009-2012
  • University of California, San Francisco, Fellow, Transplant Hepatology, 2012-2013
  • American Board of Internal Medicine
  • American Board of Internal Medicine - Gastroenterology
  • American Board of Internal Medicine - Transplant Hepatology
  • UCSF Liver Center
  • Alcoholic Liver Disease
  • Autoimmune Hepatitis
  • Cirrhosis
  • Drug-Induced Hepatitis
  • Fulminant Hepatic Failure
  • Hemochromatosis
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma (Liver Cancer)
  • Liver Transplantation
  • Living Donor Liver Transplantation
  • Nonalcoholic Fatty Liver Disease
  • Polycystic Liver Disease
  • Primary Biliary Cirrhosis
  • Primary Sclerosing Cholangitis
  • Cardiopulmonary complications of chronic liver disease
  • Hepatocellular carcinoma (HCC)
  • Liver injury and repair (Liver transplantation)
  • Liver transplantation outcomes including expanded criteria liver transplants

Dr. Neil Mehta is a general and transplant hepatologist, specializing in treating patients with hepatocellular carcinoma (HCC) and those with end-stage liver disease needing liver transplantation.

After earning his undergraduate degree from Johns Hopkins University and MD degree from UCSF, he completed residency at the Hospital of the University of Pennsylvania and both gastroenterology and advanced/transplant hepatology fellowships at UCSF. Dr. Mehta is a member of the American Association for the Study of Liver Diseases and board-certified by the American Board of Internal Medicine in Internal medicine, Gastroenterology, and Transplant Hepatology.

Dr. Mehta is engaged in research investigating clinical outcomes in patients with end-stage liver disease. His research focuses on two main areas:

  • Understanding issues related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation. Specific topics we are currently interested in are evaluating the risk of HCC recurrence post-transplant based on transplant waiting times, creating an HCC recurrence risk score, and downstaging tumors in to conventional transplant criteria.
  • Understanding the role of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Mr. Mehta is also conducting research related to the diagnosis and management of patients with hepatocellular carcinoma (HCC) particularly with regards to outcomes in liver transplantation.This includes a multicenter project with CPMC and Scripps to understand the role of downstaging tumors into conventional transplant criteria. He is also pursuing projects to address the risk of HCC recurrence post-transplant based on transplant waiting times as well as to create an HCC recurrence risk score. These projects are being done collaboratively with the Mayo clinic in Rochester and Jacksonville.

Dr. Mehta is also pursuing research to help optimize the management of iron overload in patients listed for liver transplant, specifically with regards to both hepatic and cardiac iron deposition.

Most recent publications from a total of 86
  1. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. Hepatology. 2020 Feb 04. View in PubMed
  2. Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion. Transpl Int. 2020 Jan 28. View in PubMed
  3. Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. The Impact of Direct Acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.: An International Multicenter Study. Transplantation. 2020 Jan 16. View in PubMed
  4. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. Surveillance for HCC after Liver Transplantation: Increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020 Jan 13. View in PubMed
  5. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. Hepatocellular carcinoma (HCC) patients listed in short wait regions remain advantaged for liver transplant (LT) following 2015 HCC policy change. Liver Transpl. 2019 Dec 13. View in PubMed
  6. Cullaro G, Rubin JB, Mehta N, Lai JC. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Liver Transpl. 2019 Oct 14. View in PubMed
  7. Lee E, Sarkar M, Dodge J, Kohi M, Mehta N. Shorter Height is Associated with Lower Probability of Liver Transplantation in Patients with Hepatocellular Carcinoma. Transplantation. 2019 Sep 30. View in PubMed
  8. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 Aug 02; 2(8):e1910326. View in PubMed
  9. Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study. Prehosp Disaster Med. 2019 Aug; 34(4):393-400. View in PubMed
  10. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Neil Mehta, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

 

Site Directory
    X